Antonio Abbate

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3320172/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. European Heart Journal, 2006, 27, 2667-2674.	1.0	636
2	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 2021, 21, 319-329.	10.6	594
3	The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19725-19730.	3.3	501
4	Impact of Intracoronary Cell Therapy on Left Ventricular Function in the Setting of Acute Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 1761-1767.	1.2	484
5	The NLRP3 inflammasome in acute myocardial infarction. Nature Reviews Cardiology, 2018, 15, 203-214.	6.1	466
6	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circulation Research, 2020, 126, 1260-1280.	2.0	391
7	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation, 2019, 139, 1289-1299.	1.6	384
8	Stress Cardiomyopathy Diagnosis andÂTreatment. Journal of the American College of Cardiology, 2018, 72, 1955-1971.	1.2	355
9	Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study). American Journal of Cardiology, 2010, 105, 1371-1377.e1.	0.7	346
10	Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction. Circulation, 2008, 117, 2670-2683.	1.6	309
11	Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]. American Journal of Cardiology, 2013, 111, 1394-1400.	0.7	308
12	Cirrhotic Cardiomyopathy. Journal of the American College of Cardiology, 2010, 56, 539-549.	1.2	288
13	Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity. American Journal of Cardiology, 2013, 112, 1980-1984.	0.7	264
14	Sex-Related Differences in Myocardial Remodeling. Journal of the American College of Cardiology, 2010, 55, 1057-1065.	1.2	263
15	Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 652-660.	2.5	257
16	Targeting Interleukin-1 in Heart Disease. Circulation, 2013, 128, 1910-1923.	1.6	253
17	Atherothrombosis, inflammation, and diabetes. Journal of the American College of Cardiology, 2003, 41, 1071-1077.	1.2	236
18	Exercise Intolerance in Patients With Heart Failure. Journal of the American College of Cardiology, 2019, 73, 2209-2225.	1.2	236

#	Article	IF	CITATIONS
19	Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. European Heart Journal, 2005, 26, 1196-1204.	1.0	235
20	Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H1553-H1568.	1.5	235
21	Anti-Inflammatory Strategies for Ventricular Remodeling Following ST-Segment Elevation Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 1593-1603.	1.2	234
22	Pathobiology of pulmonary arterial hypertension and right ventricular failure. European Respiratory Journal, 2012, 40, 1555-1565.	3.1	233
23	Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ, The, 2013, 346, f55-f55.	3.0	232
24	A Novel Pharmacologic Inhibitor of the NLRP3 Inflammasome Limits Myocardial Injury After Ischemia–Reperfusion in the Mouse. Journal of Cardiovascular Pharmacology, 2014, 63, 316-322.	0.8	215
25	Effects of Interleukin-1 Blockade With Anakinra on Aerobic Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction (from the D-HART Pilot Study). American Journal of Cardiology, 2014, 113, 321-327.	0.7	213
26	Management of Acute and RecurrentÂPericarditis. Journal of the American College of Cardiology, 2020, 75, 76-92.	1.2	197
27	Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure. PLoS ONE, 2012, 7, e33438.	1.1	184
28	Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence. European Journal of Cardio-thoracic Surgery, 2004, 25, 304-311.	0.6	182
29	Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. Journal of the American College of Cardiology, 2003, 41, 753-760.	1.2	175
30	Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia–reperfusion in the mouse. International Journal of Cardiology, 2016, 209, 215-220.	0.8	173
31	A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L977-L991.	1.3	171
32	Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	171
33	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. American Heart Journal, 2008, 155, 274-283.	1.2	170
34	Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine, 2021, 384, 31-41.	13.9	162
35	Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. Journal of Cellular Physiology, 2002, 193, 145-153.	2.0	159
36	Metabolic Gene Remodeling and Mitochondrial Dysfunction in Failing Right Ventricular Hypertrophy Secondary to Pulmonary Arterial Hypertension. Circulation: Heart Failure, 2013, 6, 136-144.	1.6	159

#	Article	IF	CITATIONS
37	Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Critical Care, 2020, 24, 389.	2.5	158
38	Apoptosis and Post-infarction Left Ventricular Remodeling. Journal of Molecular and Cellular Cardiology, 2002, 34, 165-174.	0.9	157
39	Interleukinâ€1 Blockade Inhibits the Acute Inflammatory Response in Patients With STâ€5egment–Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014941.	1.6	150
40	Acute myocardial infarction and heart failure: Role of apoptosis. International Journal of Biochemistry and Cell Biology, 2006, 38, 1834-1840.	1.2	146
41	Suppression of Histone Deacetylases Worsens Right Ventricular Dysfunction after Pulmonary Artery Banding in Rats. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1402-1410.	2.5	143
42	Cardiovascular Implications of the COVID-19 Pandemic: AÂGlobal Perspective. Canadian Journal of Cardiology, 2020, 36, 1068-1080.	0.8	141
43	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 230.	3.8	139
44	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 294, H1398-H1406.	1.5	138
45	Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide. Circulation, 2009, 120, S31-6.	1.6	136
46	Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ: British Medical Journal, 2006, 332, 202-209.	2.4	135
47	Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies). American Journal of Cardiology, 2015, 115, 288-292.	0.7	135
48	Interleukin-1 blockade in cardiovascular diseases: a clinical update. European Heart Journal, 2018, 39, 2063-2069.	1.0	135
49	Guidelines for evaluating myocardial cell death. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H891-H922.	1.5	135
50	Restenosis, Stent Thrombosis, and Bleeding Complications. Journal of the American College of Cardiology, 2018, 71, 1676-1695.	1.2	134
51	Effects of Sodiumâ€Glucose Cotransporter 2 Inhibitors on 24â€Hour Ambulatory Blood Pressure: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2017, 6, .	1.6	131
52	Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International Journal of Cardiology, 2011, 150, 325-331.	0.8	129
53	The Inflammasome in Myocardial Injury and Cardiac Remodeling. Antioxidants and Redox Signaling, 2015, 22, 1146-1161.	2.5	129
54	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005036.	1.6	129

#	Article	IF	CITATIONS
55	Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. Journal of Cardiovascular Pharmacology, 2015, 66, 1-8.	0.8	128
56	Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia–reperfusion injury. Journal of Molecular and Cellular Cardiology, 2011, 51, 244-251.	0.9	127
57	Left Ventricular Systolic Dysfunction Induced by Ventricular Ectopy. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 543-549.	2.1	125
58	A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. International Journal of Epidemiology, 2004, 34, 224-225.	0.9	117
59	Widespread Myocardial Inflammation and Infarct-Related Artery Patency. Circulation, 2004, 110, 46-50.	1.6	114
60	Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure. Molecular Medicine, 2014, 20, 221-229.	1.9	114
61	Interventiona€a€Conflicts of interest: Dr. Angiolillo is a consultant and on the speakera€™s bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb, Dr. Montalescot has been a consultant for and/or received	0.7	110
62	research grants from Sa. American Journal of Cardiology, 2007, 100, 1199-1206. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H1025-H1031.	1.5	110
63	Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Frontiers in Immunology, 2020, 11, 1625.	2.2	108
64	International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. American Heart Journal, 2010, 160, 662-670.	1.2	107
65	The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine, 2022, 28, 809-813.	15.2	107
66	Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatology, The, 2020, 2, e457-ee458.	2.2	106
67	Neutrophil Extracellular Traps and Cardiovascular Diseases: An Update. Cells, 2020, 9, 231.	1.8	106
68	Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. American Heart Journal, 2008, 155, 1081-1089.	1.2	105
69	Inflammasome formation in the lungs of patients with fatal COVID-19. Inflammation Research, 2021, 70, 7-10.	1.6	104
70	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1398-H1406.	1.5	102
71	Interleukinâ€lβ modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. European Journal of Heart Failure, 2010, 12, 319-322.	2.9	102
72	Innate immunity as a target for acute cardioprotection. Cardiovascular Research, 2019, 115, 1131-1142.	1.8	101

#	Article	IF	CITATIONS
73	Galectin-1 Controls Cardiac Inflammation and Ventricular Remodeling during Acute Myocardial Infarction. American Journal of Pathology, 2013, 182, 29-40.	1.9	99
74	Interleukin-1 Blockade in Acute Decompensated Heart Failure. Journal of Cardiovascular Pharmacology, 2016, 67, 544-551.	0.8	98
75	Induction of MicroRNA-21 With Exogenous Hydrogen Sulfide Attenuates Myocardial Ischemic and Inflammatory Injury in Mice. Circulation: Cardiovascular Genetics, 2014, 7, 311-320.	5.1	97
76	ldentification of Protein Disulfide Isomerase as a Cardiomyocyte Survival Factor in Ischemic Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 1029-1037.	1.2	96
77	Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure. American Journal of Cardiology, 2009, 104, 1708-1716.	0.7	93
78	Survival and Cardiac Remodeling Benefits in Patients Undergoing Late Percutaneous Coronary Intervention of the Infarct-Related Artery. Journal of the American College of Cardiology, 2008, 51, 956-964.	1.2	92
79	Interleukinâ€1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Experimental Physiology, 2013, 98, 734-745.	0.9	92
80	Heart failure with preserved ejection fraction: Refocusing on diastole. International Journal of Cardiology, 2015, 179, 430-440.	0.8	91
81	Myocardial protection from ischemia-reperfusion injury post coronary revascularization. Expert Review of Cardiovascular Therapy, 2015, 13, 1045-1057.	0.6	91
82	Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression. American Heart Journal, 2005, 149, 504-511.	1.2	90
83	Interleukin-1β induces a reversible cardiomyopathy in the mouse. Inflammation Research, 2013, 62, 637-640.	1.6	89
84	High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. Atherosclerosis, 2015, 240, 197-204.	0.4	89
85	Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization. Journal of Medicinal Chemistry, 2018, 61, 5412-5423.	2.9	89
86	Persistent Infarct–Related Artery Occlusion Is Associated With an Increased Myocardial Apoptosis at Postmortem Examination in Humans Late After an Acute Myocardial Infarction. Circulation, 2002, 106, 1051-1054.	1.6	88
87	Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2015, 22, 1435-1441.	0.8	85
88	The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse. Journal of Cardiovascular Pharmacology, 2019, 73, 215-222.	0.8	85
89	ls bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. European Heart Journal, 2005, 26, 881-889.	1.0	84
90	ILâ€18 and infections: Is there a role for targeted therapies?. Journal of Cellular Physiology, 2021, 236, 1638-1657.	2.0	83

#	Article	IF	CITATIONS
91	Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. CardioRenal Medicine, 2020, 10, 277-287.	0.7	82
92	Macrophage-Specific Lipid-Based Nanoparticles Improve Cardiac Magnetic Resonance Detection and Characterization of Human Atherosclerosis. JACC: Cardiovascular Imaging, 2009, 2, 637-647.	2.3	80
93	Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. Journal of Cardiology, 2016, 67, 125-130.	0.8	79
94	Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovascular Research, 2017, 113, cvw246.	1.8	78
95	Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transplantation, 2018, 24, 333-342.	1.3	78
96	Relation of Blood Urea Nitrogen to Long-Term Mortality in Patients With Heart Failure. American Journal of Cardiology, 2008, 101, 1643-1647.	0.7	76
97	Targeting Interleukin-1 in Heart Failure and Inflammatory Heart Disease. Current Heart Failure Reports, 2015, 12, 33-41.	1.3	76
98	IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 381-384.	2.5	75
99	Silencing of Hypoxia-Inducible Factor-1α Gene Attenuated Angiotensin II–Induced Renal Injury in Sprague-Dawley Rats. Hypertension, 2011, 58, 657-664.	1.3	74
100	Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart, 2015, 2, e000174.	0.9	74
101	Inflammatory markers in ST-elevation acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 382-395.	0.4	72
102	Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H2272-H2279.	1.5	71
103	Targeting the NLRP3 inflammasome in cardiovascular diseases. , 2022, 236, 108053.		71
104	Interleukin-1 Trap Attenuates Cardiac Remodeling After Experimental Acute Myocardial Infarction in Mice. Journal of Cardiovascular Pharmacology, 2010, 55, 117-122.	0.8	70
105	lloprost reverses established fibrosis in experimental right ventricular failure. European Respiratory Journal, 2015, 45, 449-462.	3.1	68
106	Interleukin-1β Blockade Improves Left Ventricular Systolic/Diastolic Function and Restores Contractility Reserve in Severe Ischemic Cardiomyopathy in the Mouse. Journal of Cardiovascular Pharmacology, 2014, 64, 1-6.	0.8	67
107	Formation of the inflammasome in acute myocarditis. International Journal of Cardiology, 2014, 171, e119-e121.	0.8	67
108	Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. European Heart Journal, 2005, 26, 2039-2045.	1.0	65

#	Article	IF	CITATIONS
109	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events. BioDrugs, 2012, 26, 217-233.	2.2	65
110	Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure. Journal of Cardiovascular Pharmacology, 2021, 77, 49-60.	0.8	65
111	Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovascular Revascularization Medicine, 2010, 11, 189-198.	0.3	64
112	Alterations in the Interleukin-1/Interleukin-1 Receptor Antagonist Balance Modulate Cardiac Remodeling following Myocardial Infarction in the Mouse. PLoS ONE, 2011, 6, e27923.	1.1	64
113	Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovascular Research, 2015, 105, 203-212.	1.8	64
114	Treatment of Group I Pulmonary Arterial Hypertension with Carvedilol Is Safe. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1562-1564.	2.5	63
115	Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: A meta-regression of randomized clinical trials. Atherosclerosis, 2013, 226, 178-185.	0.4	62
116	Mechanisms of Right Heart Failure—A Work in Progress and a Plea for Failure Prevention. Pulmonary Circulation, 2013, 3, 137-143.	0.8	62
117	The role of IL-6 and IL-6 blockade in COVID-19. Expert Review of Clinical Immunology, 2021, 17, 601-618.	1.3	62
118	A high-sugar and high-fat diet impairs cardiac systolic and diastolic function in mice. International Journal of Cardiology, 2015, 198, 66-69.	0.8	61
119	Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. International Journal of Cardiology, 2005, 100, 119-123.	0.8	60
120	CS-6201, a Selective Blocker of the A _{2B} Adenosine Receptor, Attenuates Cardiac Remodeling after Acute Myocardial Infarction in the Mouse. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 587-595.	1.3	60
121	Comparison of transradial coronary procedures via right radial versus left radial artery approach: A metaâ€analysis. Catheterization and Cardiovascular Interventions, 2016, 88, 1027-1033.	0.7	60
122	Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. International Journal of Cardiology, 2021, 340, 119-121.	0.8	59
123	Role of cardiac inflammation in right ventricular failure. Cardiovascular Research, 2017, 113, 1441-1452.	1.8	58
124	Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatology, The, 2021, 3, e410-e418.	2.2	57
125	Recurrent angina after coronary revascularization: a clinical challenge. European Heart Journal, 2007, 28, 1057-1065.	1.0	56
126	Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 2487-2488.	1.2	56

#	Article	IF	CITATIONS
127	Inflammatory markers following resuscitation from out-of-hospital cardiac arrest—A prospective multicenter observational study. Resuscitation, 2016, 103, 117-124.	1.3	56
128	Interleukinâ€1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (Dâ€ <scp>HART2</scp>). Clinical Cardiology, 2017, 40, 626-632.	0.7	56
129	Pharmacologic Inhibition of Myeloid Differentiation Factor 88 (MyD88) Prevents Left Ventricular Dilation and Hypertrophy After Experimental Acute Myocardial Infarction in the Mouse. Journal of Cardiovascular Pharmacology, 2010, 55, 385-390.	0.8	55
130	Specific Inhibition of Histone Deacetylase 8 Reduces Gene Expression and Production of Proinflammatory Cytokines in Vitro and in Vivo. Journal of Biological Chemistry, 2015, 290, 2368-2378.	1.6	55
131	Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 2002, 89, 372-376.	0.7	54
132	Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. American Journal of Cardiology, 2018, 122, 1366-1370.	0.7	53
133	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in Cardiovascular Diseases, 2020, 63, 570-584.	1.6	53
134	Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). Journal of Cardiovascular Pharmacology, 2020, 75, 359-367.	0.8	53
135	The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opinion on Drug Safety, 2007, 6, 397-406.	1.0	52
136	Overview and Comparison of Infectious Endocarditis and Non-infectious Endocarditis: A Review of 814 Autoptic Cases. In Vivo, 2019, 33, 1565-1572.	0.6	52
137	Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction (from the VCU-Alpha 1-RT Pilot Study). American Journal of Cardiology, 2015, 115, 8-12.	0.7	51
138	Dietary Fat, Sugar Consumption, andÂCardiorespiratoryÂFitness in PatientsÂWithÂHeartÂFailureÂWith PreservedÂEjectionÂFraction. JACC Basic To Translational Science, 2017, 2, 513-525.	1.9	51
139	Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study. Annals of the Rheumatic Diseases, 2021, 80, 1.2-2.	0.5	51
140	Low <scp>NTâ€proBNP</scp> levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Failure, 2018, 5, 372-378.	1.4	50
141	Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. Journal of Psychopharmacology, 2010, 24, 1785-1792.	2.0	49
142	Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats. European Respiratory Journal, 2013, 41, 104-114.	3.1	49
143	A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H771-H778.	1.5	49
144	Interleukin-1 blockade for the treatment of pericarditis. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 46-53.	1.4	49

#	Article	IF	CITATIONS
145	Low Density Lipoprotein Receptor-Related Protein-1 in Cardiac Inflammation and Infarct Healing. Frontiers in Cardiovascular Medicine, 2019, 6, 51.	1.1	49
146	Coronary artery bypass grafting in type II diabetic patients: a comparison between insulin-dependent and non-insulin-dependent patients at short- and mid-term follow-up. Annals of Thoracic Surgery, 2003, 76, 1149-1154.	0.7	48
147	Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat. International Journal of Cardiology, 2006, 111, 371-376.	0.8	47
148	Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors. JAMA Cardiology, 2021, 6, 1161.	3.0	46
149	Role of Apoptosis in Adverse Ventricular Remodeling. Heart Failure Clinics, 2012, 8, 79-86.	1.0	44
150	Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. Thrombosis Research, 2014, 134, 558-564.	0.8	44
151	Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities. Mediators of Inflammation, 2018, 2018, 1-11.	1.4	44
152	Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H975-H984.	1.5	43
153	RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. American Heart Journal, 2020, 228, 81-90.	1.2	43
154	The Role of NLRP3 Inflammasome in Pericarditis. JACC Basic To Translational Science, 2021, 6, 137-150.	1.9	43
155	Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: Insights from a systematic overview of randomized trials in light of the drug-eluting stent era. American Heart Journal, 2006, 151, 682-689.	1.2	41
156	Rationale and design of the Virginia Commonwealth University–Anakinra Remodeling Trialâ€3 (VCUâ€ART3): A randomized, placeboâ€controlled, doubleâ€blinded, multicenter study. Clinical Cardiology, 2018, 41, 1004-1008.	0.7	41
157	Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse. PLoS ONE, 2013, 8, e58421.	1.1	41
158	ls vasopressin superior to adrenaline or placebo in the management of cardiac arrest? A meta-analysis. Resuscitation, 2003, 59, 221-224.	1.3	40
159	No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. European Heart Journal, 2008, 29, 1795-1797.	1.0	39
160	Network meta-analysis for evidence synthesis: What is it and why is it posed to dominate cardiovascular decision making?. International Journal of Cardiology, 2015, 182, 309-314.	0.8	39
161	A review of PCSK9 inhibition and its effects beyond LDL receptors. Journal of Clinical Lipidology, 2016, 10, 1073-1080.	0.6	39
162	Inhibition of Apoptosis Signal–Regulating Kinase 1 Reduces Myocardial Ischemia–Reperfusion Injury in the Mouse. Journal of the American Heart Association, 2012, 1, e002360.	1.6	38

#	Article	IF	CITATIONS
163	Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: The LITE (Liposomal doxorubicin–Investigational chemotherapy–Tissue) Tj ETQq1 1 1055-1057.	0.78431 0.8	4 ₅ gBT /Ov€
164	A mouse model of radiation-induced cardiomyopathy. International Journal of Cardiology, 2012, 156, 231-233.	0.8	37
165	Primary and Secondary Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2018, 122, 1578-1587.	0.7	37
166	Lifestyle Interventions with a Focus on Nutritional Strategies to Increase Cardiorespiratory Fitness in Chronic Obstructive Pulmonary Disease, Heart Failure, Obesity, Sarcopenia, and Frailty. Nutrients, 2019, 11, 2849.	1.7	37
167	Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 503-510.	1.4	37
168	Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. American Journal of Cardiology, 2019, 123, 466-473.	0.7	36
169	Late percutaneous coronary intervention for the totally occluded infarctâ€related artery: A metaâ€analysis of the effects on cardiac function and remodeling. Catheterization and Cardiovascular Interventions, 2008, 71, 772-781.	0.7	35
170	Left Circumflex Occlusion in Acute Myocardial Infarction (from the National Cardiovascular Data) Tj ETQq0 0 0 rgE	3T/Overloo 0.7	ck 10 Tf 50
171	Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse. Cardiovascular Drugs and Therapy, 2012, 26, 273-276.	1.3	34
172	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. , 2020, 2, e0178.		34
173	The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia. Methods in Enzymology, 2011, 489, 47-65.	0.4	33
174	Stellate ganglion blockade and bilateral cardiac sympathetic denervation in patients with lifeâ€ŧhreatening ventricular arrhythmias. Journal of Cardiovascular Electrophysiology, 2017, 28, 903-908.	0.8	33
175	Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart, 2021, 107, 488-496.	1.2	33
176	NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases. Molecules, 2021, 26, 976.	1.7	33
177	Right Ventricular Dysfunction following Acute Myocardial Infarction in the Absence of Pulmonary Hypertension in the Mouse. PLoS ONE, 2011, 6, e18102.	1.1	33
178	C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary Syndromes. Seminars in Vascular Medicine, 2003, 03, 375-384.	2.1	32
179	Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America. Chest, 2020, 158, 2556-2567.	0.4	32
180	Exercise intolerance in kidney diseases: physiological contributors and therapeutic strategies. American Journal of Physiology - Renal Physiology, 2021, 320, F161-F173.	1.3	32

#	Article	IF	CITATIONS
181	The association between coronary graft patency and clinical status in patients with coronary artery disease. European Heart Journal, 2021, 42, 1433-1441.	1.0	32
182	Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. International Journal of Cardiology, 2005, 99, 337-339.	0.8	31
183	Sudden Cardiac Death in Patients With Silent Myocardial Ischemia After Myocardial Infarction (from) Tj ETQq1 1 (2009, 104, 158-163.).784314 r 0.7	gBT /Overlo 31
184	Role of Interleukin-1 in Radiation-Induced Cardiomyopathy. Molecular Medicine, 2015, 21, 210-218.	1.9	31
185	Reduction of Myocardial Ischemia–Reperfusion Injury by Inhibiting Interleukin-1 Alpha. Journal of Cardiovascular Pharmacology, 2017, 69, 156-160.	0.8	31
186	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. Mayo Clinic Proceedings, 2018, 93, 1629-1647.	1.4	31
187	Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2002, 14, 139-143.	1.0	30
188	Right Ventricular Cardiomyocyte Apoptosis in Patients With Acute Myocardial Infarction of the Left Ventricular Wall. American Journal of Cardiology, 2008, 102, 658-662.	0.7	30
189	Apoptosis in Patients With Acute Myocarditis. American Journal of Cardiology, 2009, 104, 995-1000.	0.7	30
190	Anakinra in Experimental Acute Myocardial Infarction—Does Dosage or Duration of Treatment Matter?. Cardiovascular Drugs and Therapy, 2009, 23, 129-135.	1.3	30
191	The heart on fire: inflammasome and cardiomyopathy. Experimental Physiology, 2013, 98, 385-385.	0.9	30
192	IPW-5371 Proves Effective as a Radiation Countermeasure by Mitigating Radiation-Induced Late Effects. Radiation Research, 2016, 186, 478-488.	0.7	30
193	The relationship between coronary artery disease and cardiovascular events early after liver transplantation. Liver International, 2019, 39, 1363-1371.	1.9	30
194	Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e69-e70.	1.4	30
195	Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. European Heart Journal, 2022, 43, 2946-2957.	1.0	30
196	Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside. BioDrugs, 2018, 32, 111-118.	2.2	29
197	Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. Inflammation Research, 2022, 71, 293-307.	1.6	29
198	Early and long-term results of stenting of diffuse coronary artery disease. American Journal of Cardiology, 2000, 86, 1166-1170.	0.7	28

#	Article	IF	CITATIONS
199	Electron microscopy characterization of cardiomyocyte apoptosis in ischemic heart disease. International Journal of Cardiology, 2007, 114, 118-120.	0.8	28
200	Increased Eicosanoid Levels in the Sugen/Chronic Hypoxia Model of Severe Pulmonary Hypertension. PLoS ONE, 2015, 10, e0120157.	1.1	28
201	Low-Density Lipoprotein Receptor–Related Protein-1 Is a Therapeutic Target in AcuteÂMyocardial Infarction. JACC Basic To Translational Science, 2017, 2, 561-574.	1.9	28
202	Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF. JACC Basic To Translational Science, 2019, 4, 563-565.	1.9	28
203	Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. International Journal of Infectious Diseases, 2020, 100, 421-424.	1.5	28
204	Altered Oxido-Reductive State in the Diabetic Heart: Loss of Cardioprotection due to Protein Disulfide Isomerase. Molecular Medicine, 2011, 17, 1012-1021.	1.9	27
205	State of the Art on the Evidence Base in Cardiac Regenerative Therapy: Overview of 41 Systematic Reviews. BioMed Research International, 2015, 2015, 1-7.	0.9	27
206	Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac Death. International Journal of Molecular Sciences, 2016, 17, 958.	1.8	27
207	The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The <scp>CANAâ€HF</scp> study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3335.	1.7	27
208	Fatal pulmonary arterial dissection and sudden death as initial manifestation of primary pulmonary hypertension. Cardiovascular Pathology, 2004, 13, 230-232.	0.7	26
209	Is Late Luminal Loss an Accurate Predictor of the Clinical Effectiveness of Drug-Eluting Stents in the Coronary Arteries?. American Journal of Cardiology, 2006, 97, 603-605.	0.7	26
210	Severe Pulmonary Hypertension: The Role of Metabolic and Endocrine Disorders. Pulmonary Circulation, 2012, 2, 148-154.	0.8	26
211	Vascular Endothelial Growth Factor Receptor 3 Signaling Contributes to Angioobliterative Pulmonary Hypertension. Pulmonary Circulation, 2015, 5, 101-116.	0.8	26
212	Characterization of mitochondrial injury after cardiac arrest (COMICA). Resuscitation, 2017, 113, 56-62.	1.3	26
213	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. Diabetes, Obesity and Metabolism, 2018, 20, 2014-2018.	2.2	26
214	Right atrium tear as cause of death after blunt chest trauma. Injury, 2006, 37, 81-82.	0.7	25
215	Drug Insight: statins for nonischemic heart failure—evidence and potential mechanisms. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 196-205.	3.3	25
216	Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes. Clinical Chemistry, 2009, 55, 365-368.	1.5	25

#	Article	IF	CITATIONS
217	Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction. International Journal of Molecular Sciences, 2019, 20, 544.	1.8	25
218	Percutaneous renal artery intervention versus medical therapy in patients with renal artery stenosis: a meta-analysis. EuroIntervention, 2011, 7, 844-851.	1.4	25
219	Temporal Changes in Standard and Tissue Doppler Imaging Echocardiographic Parameters After Anthracycline Chemotherapy in Women With Breast Cancer. American Journal of Cardiology, 2013, 112, 1005-1012.	0.7	24
220	A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. Journal of Cardiovascular Medicine, 2015, 16, 839-843.	0.6	24
221	Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). Journal of Cardiovascular Pharmacology, 2019, 74, 266-269.	0.8	24
222	Pharmacologic Inhibition of Phosphoinositide 3-Kinase Gamma (PI3Kγ) Promotes Infarct Resorption and Prevents Adverse Cardiac Remodeling After Myocardial Infarction in Mice. Journal of Cardiovascular Pharmacology, 2010, 56, 651-658.	0.8	23
223	Sympathectomy as a treatment for refractory coronary artery spasm. International Journal of Cardiology, 2012, 161, e7-e9.	0.8	23
224	Role of NLRP3 (cryopyrin) in acute myocardial infarction. Cardiovascular Research, 2013, 99, 225-226.	1.8	23
225	Novel Trial Design: CHIEF-HF. Circulation: Heart Failure, 2021, 14, e007767.	1.6	23
226	Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART). Journal of Translational Medicine, 2021, 19, 460.	1.8	23
227	Protective Effects of Parecoxib, a Cyclo-Oxygenase-2 Inhibitor, in Postinfarction Remodeling in the Rat. Journal of Cardiovascular Pharmacology, 2007, 50, 571-577.	0.8	22
228	Relaxin' the Heart. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 353-362.	1.0	22
229	Cardiac arrest due to ventricular fibrillation in a 23-year-old woman with broken heart syndrome. Cardiovascular Pathology, 2017, 30, 78-81.	0.7	22
230	An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet–Induced Cardiac Dysfunction in Mice. Journal of Cardiovascular Pharmacology, 2018, 72, 303-307.	0.8	22
231	Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease. International Journal of Cardiology, 2004, 94, 105-110.	0.8	21
232	Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. International Journal of Cardiology, 2007, 114, 104-105.	0.8	21
233	Cardiologic side effects of psychotropic drugs. Journal of Geriatric Cardiology, 2012, 8, 243-253.	0.2	21
234	Mitochondrial Membrane Permeability Inhibitors in Acute Myocardial Infarction. JACC Basic To Translational Science, 2016, 1, 524-535.	1.9	21

#	Article	IF	CITATIONS
235	Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients With Chronic Systolic Heart Failure. American Journal of Cardiology, 2016, 117, 116-120.	0.7	21
236	Inhibiting the Inflammatory Injury After Myocardial Ischemia Reperfusion With Plasma-Derived Alpha-1 Antitrypsin: A Post Hoc Analysis of the VCU-α1RT Study. Journal of Cardiovascular Pharmacology, 2018, 71, 375-379.	0.8	21
237	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. Frontiers in Cardiovascular Medicine, 2018, 5, 178.	1.1	21
238	How Can Interleukin-1 Receptor Antagonist Modulate Distinct Cell Death Pathways?. Journal of Chemical Information and Modeling, 2019, 59, 351-359.	2.5	21
239	Percutaneous coronary intervention in nonagenarians: pros and cons. Journal of Geriatric Cardiology, 2013, 10, 82-90.	0.2	21
240	A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy. BioMed Research International, 2014, 2014, 1-9.	0.9	20
241	Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?. European Heart Journal, 2015, 36, 337-339.	1.0	20
242	Recombinant Human Alpha-1 Antitrypsin-Fc Fusion Protein Reduces Mouse Myocardial Inflammatory Injury After Ischemia–Reperfusion Independent of Elastase Inhibition. Journal of Cardiovascular Pharmacology, 2016, 68, 27-32.	0.8	20
243	Resolution of pericardial constriction with Anakinra in a patient with effusive-constrictive pericarditis secondary to rheumatoid arthritis. International Journal of Cardiology, 2016, 223, 215-216.	0.8	20
244	Inflammasome Formation in Granulomas in Cardiac Sarcoidosis. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007582.	2.1	20
245	Metabolic modulation predicts heart failure tests performance. PLoS ONE, 2019, 14, e0218153.	1.1	20
246	Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. Journal of Cardiovascular Pharmacology, 2020, 76, 50-52.	0.8	20
247	Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points. International Journal of Cardiology, 2009, 135, 72-77.	0.8	19
248	Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work. Journal of Cardiovascular Pharmacology, 2018, 72, 68-70.	0.8	19
249	Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis. Current Atherosclerosis Reports, 2020, 22, 45.	2.0	19
250	Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177® (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction. Molecules, 2021, 26, 3534.	1.7	19
251	The â€~Open-Artery Hypothesis': New Clinical and Pathophysiologic Insights. Cardiology, 2003, 100, 196-206.	0.6	18
252	Role of apoptosis in pressure-overload cardiomyopathy. Journal of Cardiovascular Medicine, 2008, 9, 227-232.	0.6	18

#	Article	IF	CITATIONS
253	Hypoplastic coronary artery disease causing sudden death. Report of two cases and review of the literature. Cardiovascular Pathology, 2010, 19, e107-e111.	0.7	18
254	A model of acute kidney injury in mice with cirrhosis and infection. Liver International, 2016, 36, 865-873.	1.9	18
255	Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. ESC Heart Failure, 2017, 4, 351-355.	1.4	18
256	Inflammatory markers and coronary interventions: A potentially useful follow-up modality after stenting. Catheterization and Cardiovascular Interventions, 2002, 56, 341-345.	0.7	17
257	Improvement of Cardiac Function With Parecoxib, A Cyclo-oxygenase-2 Inhibitor, in a Rat Model of Ischemic Heart Failure. Journal of Cardiovascular Pharmacology, 2007, 49, 416-418.	0.8	17
258	Parecoxib Inhibits Apoptosis in Acute Myocardial Infarction Due to Permanent Coronary Ligation But Not Due to Ischemia-Reperfusion. Journal of Cardiovascular Pharmacology, 2009, 53, 495-498.	0.8	17
259	Interleukin-1 blockade in rheumatoid arthritis and heart failure: A missed opportunity?. International Journal of Cardiology, 2014, 171, e125-e126.	0.8	17
260	Determinants of Cardiorespiratory Fitness Following Thoracic Radiotherapy in Lung or Breast Cancer Survivors. American Journal of Cardiology, 2020, 125, 988-996.	0.7	17
261	Cardiopulmonary exercise testing – refining the clinical perspective by combining assessments. Expert Review of Cardiovascular Therapy, 2020, 18, 563-576.	0.6	17
262	Ethical Criteria for the Admission and Management of Patients in the ICU Under Conditions of Limited Medical Resources: A Shared International Proposal in View of the COVID-19 Pandemic. Frontiers in Public Health, 2020, 8, 284.	1.3	17
263	An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Medica, 2021, 63, 249-260.	0.2	17
264	Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling. Current Problems in Cardiology, 2023, 48, 101215.	1.1	17
265	Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression. American Heart Journal, 2007, 153, 587-593.	1.2	16
266	Intracellular Function of Interleukin-1 Receptor Antagonist in Ischemic Cardiomyocytes. PLoS ONE, 2013, 8, e53265.	1.1	16
267	Derivation and validation of a simple inflammation-based risk score system for predicting in-hospital mortality in acute coronary syndrome patients. Journal of Cardiology, 2019, 73, 416-424.	0.8	16
268	ST segment elevation and new right bundle branch block: Broadening the differential diagnosis. International Journal of Cardiology, 2007, 114, 247-248.	0.8	15
269	Depression and the cardiovascular system: increasing evidence of a link and therapeutic implications. Expert Review of Cardiovascular Therapy, 2009, 7, 1123-1147.	0.6	15
270	Biomarkers of cardiac injury in patients undergoing thoracic radiation therapy. International Journal of Cardiology, 2016, 223, 507-509.	0.8	15

#	Article	IF	CITATIONS
271	A Preclinical Translational Study of the Cardioprotective Effects of Plasma-Derived Alpha-1 Anti-trypsin in Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology, 2017, 69, 273-278.	0.8	15
272	Interplay of inflammation, oxidative stress and cardiovascular disease in rheumatoid arthritis. Heart, 2018, 104, 1991-1992.	1.2	15
273	Inflammation and Hypertension. Hypertension, 2020, 75, 297-298.	1.3	15
274	Cardiopulmonary exercise testing during the COVID-19 pandemic. Progress in Cardiovascular Diseases, 2021, 67, 35-39.	1.6	15
275	Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction. Scientific Reports, 2022, 12, 1254.	1.6	15
276	Cellular preservation therapy in acute myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H563-H565.	1.5	14
277	Formation of the inflammasome during cardiac allograft rejection. International Journal of Cardiology, 2015, 201, 328-330.	0.8	14
278	Heart failure in patients with human immunodeficiency virus. Journal of Cardiovascular Medicine, 2015, 16, 383-389.	0.6	14
279	Development of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Progress in Cardiovascular Diseases, 2016, 59, 52-58.	1.6	14
280	Thoracic Sympathectomy for Severe Refractory Multivessel Coronary Artery Spasm. American Journal of Cardiology, 2016, 117, 159-161.	0.7	14
281	Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial. Frontiers in Psychiatry, 2021, 12, 666945.	1.3	14
282	Non-atherosclerotic coronary pathology causing sudden death. Journal of Clinical Pathology, 2007, 60, 94-97.	1.0	13
283	Clinical Outcomes in Patients with Acute Left Circumflex/Obtuse Marginal Occlusion Presenting with Myocardial Infarction. Journal of Interventional Cardiology, 2011, 24, 27-33.	0.5	13
284	Life-Saving Systemic Thrombolysis in a Patient with Massive Pulmonary Embolism and a Recent Hemorrhagic Cerebrovascular Accident. Texas Heart Institute Journal, 2014, 41, 174-176.	0.1	13
285	Takotsubo syndrome. Current Opinion in Cardiology, 2019, 34, 673-686.	0.8	13
286	Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy. Cardio-Oncology, 2020, 6, 2.	0.8	13
287	Role of endothelial dysfunction in determining angina after percutaneous coronary intervention: Learning from pathophysiology to optimize treatment. Progress in Cardiovascular Diseases, 2020, 63, 233-242.	1.6	13
288	Stenting techniques for coronary bifurcation lesions: Evidence from a network metaâ€analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions, 2021, 97, E306-E318.	0.7	13

#	Article	IF	CITATIONS
289	The inflammasome in heart failure. Current Opinion in Physiology, 2021, 19, 105-112.	0.9	13
290	Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Current Cardiology Reports, 2021, 23, 157.	1.3	13
291	Ischemia and apoptosis in an animal model of permanent infarct-related artery occlusion. International Journal of Cardiology, 2007, 121, 109-111.	0.8	12
292	Leukocyte Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction Treated with Anakinra. Molecular Medicine, 2014, 20, 486-489.	1.9	12
293	Interleukin-1 Blockade in Acute MyocardialÂInfarction and Heart Failure. JACC Basic To Translational Science, 2017, 2, 431-433.	1.9	12
294	Why the CANTOS Is a Game Changer in Cardiovascular Medicine. Journal of Cardiovascular Pharmacology, 2017, 70, 353-355.	0.8	12
295	Determination of Optimal Coronary Flow for the Preservation of "Donation after Circulatory Death― in Murine Heart Model. ASAIO Journal, 2018, 64, 225-231.	0.9	12
296	Structural Stress and Otherness: How Do They Influence Psychological Stress?. Journal of Transcultural Nursing, 2019, 30, 478-491.	0.6	12
297	Parallel hierarchy of scientific studies in cardiovascular medicine. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2003, 4, 819-20.	0.1	12
298	Safety of Drug-Eluting Stents in Patients With Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2008, 102, 679-682.	0.7	11
299	Potential Pitfalls of Meta-Analyses of Observational Studies in Cardiovascular Research. Journal of the American College of Cardiology, 2012, 59, 292-293.	1.2	11
300	Lack of soluble circulating cardiodepressant factors in takotsubo cardiomyopathy. Autonomic Neuroscience: Basic and Clinical, 2017, 208, 170-172.	1.4	11
301	Confirmed marijuana use and lymphocyte count in black people living with HIV. Drug and Alcohol Dependence, 2019, 198, 112-115.	1.6	11
302	Response to: â€~Correspondence on â€~Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study' by Potere <i>et al'</i> by Buckley. Annals of the Rheumatic Diseases, 2022, 81, e195-e195.	0.5	11
303	Hydrogen Sulfide Therapy Suppresses Cofilin-2 and Attenuates Ischemic Heart Failure in a Mouse Model of Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 472-483.	1.0	11
304	Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents. Current Atherosclerosis Reports, 2020, 22, 4.	2.0	11
305	Plasma concentrations of interleukin-2 soluble receptor in mild ischaemic left ventricular dysfunction. European Journal of Heart Failure, 2003, 5, 23-25.	2.9	10
306	The difficult task of glycaemic control in diabetics with acute coronary syndromes: finding the way to normoglycaemia avoiding both hyper- and hypoglycaemiaThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2005, 26, 1245-1248.	1.0	10

#	Article	IF	CITATIONS
307	Coronary stenting versus balloon angioplasty in small vessels. Journal of the American College of Cardiology, 2005, 45, 323-324.	1.2	10
308	Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial. European Heart Journal, 2007, 28, 1782-1783.	1.0	10
309	Left Ventricular Diastolic Filling Pattern at Doppler Echocardiography and Apoptotic Rate in Fatal Acute Myocardial Infarction. American Journal of Cardiology, 2007, 99, 307-309.	0.7	10
310	Causation or coincidence? A case of sudden death due to spontaneous coronary artery dissection in presence of myocardial bridging. International Journal of Cardiology, 2012, 159, e32-e34.	0.8	10
311	Aspirin underuse, non-compliance or cessation: Definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease. International Journal of Cardiology, 2015, 182, 148-154.	0.8	10
312	Severely Impaired Cardiorespiratory Fitness in Patients With Recently Decompensated Systolic Heart Failure. American Journal of Cardiology, 2017, 120, 1854-1857.	0.7	10
313	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Design, Development and Therapy, 2017, Volume 11, 2121-2129.	2.0	10
314	Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. American Journal of Cardiology, 2020, 125, 76-81.	0.7	10
315	Interleukin-10 in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2014, 172, e6-e8.	0.8	9
316	Potential role for interleukinâ€1 in the cardioâ€renal syndrome. European Journal of Heart Failure, 2019, 21, 385-386.	2.9	9
317	Cardiac MRI utilizing late gadolinium enhancement (LGE) and T1 mapping in the detection of radiation induced heart disease. Cardio-Oncology, 2020, 6, 6.	0.8	9
318	Hypertension guidelines and coronary artery calcification among South Asians: Results from MASALA and MESA. American Journal of Preventive Cardiology, 2021, 6, 100158.	1.3	9
319	Hemoglobin Levels Predict Exercise Performance, STâ€6egment Depression, and Outcome in Patients Referred for Routine Exercise Treadmill Testing. Clinical Cardiology, 2009, 32, E22-31.	0.7	8
320	Pharmacologic and Surgical Interventions to Improve Functional Capacity in Heart Failure. Heart Failure Clinics, 2015, 11, 117-124.	1.0	8
321	Pulmonary arterial hypertension and the Enigma code of smouldering inflammation. European Respiratory Journal, 2016, 48, 305-307.	3.1	8
322	Re. "NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective― Biochemical and Biophysical Research Communications, 2016, 470, 811-812.	1.0	8
323	The Mediterranean Diet toÂTreat Heart Failure. JACC: Heart Failure, 2018, 6, 264.	1.9	8
324	Altered Effective Connectivity of Central Autonomic Network in Response to Negative Facial Expression in Adults With Cannabis Use Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 84-96.	1.1	8

#	Article	IF	CITATIONS
325	Resting-State Directional Connectivity and Anxiety and Depression Symptoms in Adult Cannabis Users. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 545-555.	1.1	8
326	Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept. BMC Cardiovascular Disorders, 2021, 21, 201.	0.7	8
327	Clinical manifestations of coronary aneurysms in the adult as possible sequelae of Kawasaki disease during infancy. Acta Cardiologica, 2004, 59, 5-9.	0.3	8
328	Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study. Journal of Translational Medicine, 2022, 20, .	1.8	8
329	Catheter-induced straightening of external iliac tortuosity: a cause of pseudostenosis to be borne in mind. International Journal of Cardiology, 2005, 101, 333-334.	0.8	7
330	Use of a novel high-osmolar gadolinium chelate, gadobutrol, for percutaneous renal artery stenting in two patients with chronic renal failure. International Journal of Cardiology, 2005, 102, 361-362.	0.8	7
331	Bi-fascicular block on EKG as the initial presenting sign of cardiac sarcoidosis. International Journal of Cardiology, 2007, 118, e1-e2.	0.8	7
332	Low Diagnostic Yield of Elective Coronary Angiography. New England Journal of Medicine, 2010, 363, 92-95.	13.9	7
333	Clinical predictors of response to anakinra in patients with heart failure. International Journal of Cardiology, 2014, 173, 537-539.	0.8	7
334	Potassium levels in acute myocardial infarction: definitely worth paying attention to. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 252-253.	1.4	7
335	Exercise Capacity in Patients with the Total Artificial Heart. ASAIO Journal, 2019, 65, 36-42.	0.9	7
336	Mitigation of Radiation-Induced Lung and Heart Injuries in Mice by Oral Sepiapterin after Irradiation. Radiation Research, 2021, 195, 463-473.	0.7	7
337	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. PLoS ONE, 2021, 16, e0247357.	1.1	7
338	Percutaneous coronary stenting in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. EuroIntervention, 2007, 3, 409-415.	1.4	7
339	An unusual cause of fatal pulmonary embolism. International Journal of Cardiology, 2007, 114, 393-395.	0.8	6
340	Agreement between adjusted indirect comparison and simplified network meta-analyses on prasugrel and ticagrelor (Reply to Passaro et al. — Int J Cardiol 2011). International Journal of Cardiology, 2011, 151, 228-229.	0.8	6
341	It's never too early! Evidence for rushing your acute coronary patients to the cath lab. European Heart Journal, 2011, 32, 13-15.	1.0	6
342	Right ventricular systolic dysfunction in patients with reperfused ST-segment elevation acute myocardial infarction. International Journal of Cardiology, 2012, 155, 314-316.	0.8	6

#	Article	IF	CITATIONS
343	An unusual presentation of chest pain: Needle perforation of the right ventricle. Heart and Lung: Journal of Acute and Critical Care, 2013, 42, 218-220.	0.8	6
344	Commentary: Observations, Trials, and Meta-Analyses: The Life Cycle of Evidence-Based Endovascular Therapy. Journal of Endovascular Therapy, 2014, 21, 693-696.	0.8	6
345	Anti-inflammatory therapies in myocardial infarction. Lancet, The, 2015, 385, 2573-2574.	6.3	6
346	Idiopathic sensorineural hearing loss is associated with endothelial dysfunction. IJC Heart and Vasculature, 2016, 12, 32-33.	0.6	6
347	Evidence-Based Psychotherapy in Ischemic Heart Disease: Umbrella Review and Updated Meta-Analysis. , 2016, , 131-158.		6
348	Comparison of Cardiorespiratory Fitness in Black or African American Versus Caucasian Patients With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2022, 42, 39-44.	1.2	6
349	Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. Journal of Clinical and Translational Science, 2021, 5, e136.	0.3	6
350	Advances in pharmacotherapy for acute and recurrent pericarditis. Expert Opinion on Pharmacotherapy, 2022, 23, 681-691.	0.9	6
351	Active Surveillance Cultures and Procalcitonin in Combination With Clinical Data to Guide Empirical Antimicrobial Therapy in Hospitalized Medical Patients With Sepsis. Frontiers in Microbiology, 2022, 13, 797932.	1.5	6
352	Takotsubo Syndrome in Intensive Cardiac Care Unit: Challenges in Diagnosis and Management. Current Problems in Cardiology, 2022, 47, 101084.	1.1	6
353	The inflammasome as a therapeutic target for myopericardial diseases. Minerva Cardiology and Angiology, 2022, 70, 238-247.	0.4	6
354	Select drug-drug interactions with colchicine and cardiovascular medications: A review. American Heart Journal, 2022, 252, 42-50.	1.2	6
355	B-Type Natriuretic Peptide and Acute Coronary Syndromes. New England Journal of Medicine, 2002, 346, 453-455.	13.9	5
356	Left ventricular hypertrophy, apoptosis, and progression to heart failure in severe aortic stenosis. European Heart Journal, 2005, 26, 2747-2747.	1.0	5
357	Rescue percutaneous coronary intervention for failed thrombolysis in a patient with anomalous coronary arteries. International Journal of Cardiology, 2005, 99, 325-326.	0.8	5
358	Asphyxia in a confined space. Medicine, Science and the Law, 2007, 47, 165-170.	0.6	5
359	Diet-Induced Obesity HFpEF Murine Models. JACC Basic To Translational Science, 2018, 3, 157.	1.9	5
360	Drugs to Inhibit the NLRP3 Inflammasome. Journal of Cardiovascular Pharmacology, 2019, 74, 225-227.	0.8	5

#	Article	IF	CITATIONS
361	In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?. Journal of Cardiovascular Pharmacology, 2019, 74, 1-3.	0.8	5
362	The Chronic Kidney Disease Phenotype of HFpEF: Unique Cardiac Characteristics. American Journal of Cardiology, 2021, 142, 143-145.	0.7	5
363	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE–TIMI 60 trial. American Heart Journal, 2022, 243, 147-157.	1.2	5
364	COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events. Minerva Cardioangiologica, 2020, 68, 5-8.	1.2	5
365	Biologic Therapy for Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis: Systematic Review with Pairwise and Network Meta-Analysis. International Journal of Statistics in Medical Research, 2014, 3, 74-87.	0.5	5
366	Spontaneous Rupture of Coronary Artery in Human Immunodeficiency Virus–Positive Patient Treated With Highly Active Anti-Retroviral Therapy (HAART). American Journal of Forensic Medicine and Pathology, 2005, 26, 197.	0.4	5
367	Influence of extracellular volume fraction on peak exercise oxygen pulse following thoracic radiotherapy. Cardio-Oncology, 2022, 8, 1.	0.8	5
368	Diabetes mellitus and heart failure: an update on pathophysiology and therapy. Minerva Cardiology and Angiology, 2022, , .	0.4	5
369	Effect of IL-1 Blockade with Anakinra on Heart Failure Outcomes in Patients with Anterior versus Non-Anterior STEMI. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	5
370	Potential Antiapoptotic Activity of Aldosterone Antagonists in Postinfarction Remodeling. Circulation, 2003, 108, e26.	1.6	4
371	ST-segment elevation acute myocardial infarction: reperfusion at any cost?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2005, 26, 1813-1815.	1.0	4
372	Long-term effect of chronic oral anticoagulation: focus on coronary artery disease. Future Cardiology, 2009, 5, 259-271.	0.5	4
373	Autonomic instability and asystole: Broadening the differential diagnosis of cardiac arrhythmias. International Journal of Cardiology, 2016, 220, 665-667.	0.8	4
374	Lack of Benefit for Liraglutide in Heart Failure. JAMA - Journal of the American Medical Association, 2016, 316, 2429.	3.8	4
375	Sacubitril–Valsartan for the Treatment of Heart Failure. Journal of Cardiovascular Pharmacology, 2020, 75, 105-107.	0.8	4
376	Recurrent pericarditis: an update on diagnosis and management. Panminerva Medica, 2021, 63, 261-269.	0.2	4
377	Edema Index Predicts Cardiorespiratory Fitness in Patients With Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e018631.	1.6	4
378	Time of eating and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction and obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2471-2473.	1.1	4

#	Article	IF	CITATIONS
379	Diastolic Dysfunction Contributes to Impaired Cardiorespiratory Fitness in Patients with Lung Cancer and Reduced Lung Function Following Chest Radiation. Lung, 2021, 199, 403-407.	1.4	4
380	Final results of the ISCHEMIA trial: distinguishing mass media coverage from clinical interpretation. Minerva Cardioangiologica, 2020, 68, 9-14.	1.2	4
381	Systematic reviews and meta-analyses "For Dummies― EuroIntervention, 2009, 5, 289-291.	1.4	4
382	The interleukin-1 receptor type I promotes the development of aging-associated cardiomyopathy in mice. Cytokine, 2022, 151, 155811.	1.4	4
383	Midpoint of energy intake, non-fasting time and cardiorespiratory fitness in heart failure with preserved ejection fraction and obesity. International Journal of Cardiology, 2022, 355, 23-27.	0.8	4
384	Hibernating myocardium, apoptosis, and a simple mathematical task. Journal of the American College of Cardiology, 2005, 45, 466.	1.2	3
385	The future of new aortic valve replacement approaches. Future Cardiology, 2010, 6, 351-360.	0.5	3
386	Recurrent ventricular fibrillation in a young female carrying a previously unidentified RyR2 gene mutation. International Journal of Cardiology, 2015, 201, 222-224.	0.8	3
387	Noncompliance and Cessation of DualÂAntiplatelet Therapy After CoronaryÂStenting. JACC: Cardiovascular Interventions, 2015, 8, 411-413.	1.1	3
388	Letter by Carbone et al Regarding Article, "Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction― Circulation, 2018, 137, 414-415.	1.6	3
389	Associations of fats and carbohydrates with cardiovascular disease and mortality—PURE and simple?. Lancet, The, 2018, 391, 1679.	6.3	3
390	Levosimendan in Advanced Heart Failure: Where Do We Stand?. Journal of Cardiovascular Pharmacology, 2018, 71, 127-128.	0.8	3
391	Comment on Stiermaier et al. Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry. Diabetes Care 2018;41:1084–1088. Diabetes Care, 2018, 41, e121-e121.	4.3	3
392	Peak Oxygen Uptake Recovery Delay After Maximal Exercise in Patients With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2020, 40, 434-437.	1.2	3
393	Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. Minerva Medica, 2021, , .	0.3	3
394	Clarification Regarding the Lack of HeartÂFailure Events in the ASSAIL-MI Trial. Journal of the American College of Cardiology, 2021, 78, 637.	1.2	3
395	Preservation of Cardiac Reserve and Cardiorespiratory Fitness in Patients With Acute De Novo Versus Acute on Chronic Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2021, 158, 74-80.	0.7	3
396	Pericarditis Recurrence After Initial Uncomplicated Clinical Course. American Journal of Cardiology, 2021, 160, 112-116.	0.7	3

#	Article	IF	CITATIONS
397	Left ventricular concentric remodeling and impaired cardiorespiratory fitness in patients with heart failure and preserved ejection fraction. Minerva Cardiology and Angiology, 2021, 69, 438-445.	0.4	3
398	Prasugrel During Primary Percutaneous Coronary Intervention: Evidence from Clinical Data. Current Vascular Pharmacology, 2012, 10, 454-457.	0.8	3
399	Minerva Cardioangiologica: glancing backward, rushing forward. Minerva Cardioangiologica, 2020, 68, .	1.2	3
400	Spontaneous rupture of coronary artery in human immunodeficiency virus-positive patient treated with highly active anti-retroviral therapy (HAART). American Journal of Forensic Medicine and Pathology, 2005, 26, 197.	0.4	3
401	Myocarditis after RNA-based COVID-19 vaccines: Where do we stand?. International Journal of Cardiology, 2022, 356, 81-82.	0.8	3
402	Clinical features and outcomes between African American and Caucasian patients with Takotsubo Syndrome. Minerva Cardiology and Angiology, 2021, 69, 750-759.	0.4	3
403	PCNA expression in ischemic cardiomyopathy: DNA repair, myocyte regeneration or just another type of myocyte death?. International Journal of Cardiology, 2004, 97, 153-154.	0.8	2
404	Fatal choking due to amyloid infiltration of the laryngeal plexus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 115-116.	1.4	2
405	Critical role of bare-metal stent controls in trials of drug-eluting stents. European Heart Journal, 2005, 26, 1686-1687.	1.0	2
406	Low-Dose Aspirin for Stroke Prevention. Stroke, 2006, 37, 1356-1356.	1.0	2
407	Keeping a high standard in quantitative analyses, meta-analyses, and systematic reviews. European Heart Journal, 2007, 28, 516-517.	1.0	2
408	Letters to the Editor. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 816-817.	0.4	2
409	Limited value of brain natriuretic peptide as a prognostic marker in acute heart failure — A meta-analysis. International Journal of Cardiology, 2010, 145, 540-541.	0.8	2
410	Can we predict which patients with ST-elevation myocardial infarction benefit most from radial access? Evidence from frequentist and Bayesian meta-regressions of randomized trials. International Journal of Cardiology, 2013, 168, 4931-4934.	0.8	2
411	Response to Letter Regarding Article, "Targeting Interleukin-1 in Heart Disease― Circulation, 2014, 130, e63.	1.6	2
412	Inflammasome: a new villain in heart disease. Inflammasome, 2014, 1, .	0.6	2
413	An International Survey on Taking Up a Career in Cardiovascular Research: Opportunities and Biases toward Would-Be Physician-Scientists. PLoS ONE, 2015, 10, e0131900.	1.1	2
414	Pharmacists as Integral Members of the Cardiovascular Team. JAMA Cardiology, 2017, 2, 1279.	3.0	2

#	Article	IF	CITATIONS
415	Inflammation and Dysmetabolism in Systemic Autoimmune Diseases. Journal of Immunology Research, 2019, 2019, 1-2.	0.9	2
416	Letter by Del Buono et al Regarding Article, "A Simple, Evidence-Based Approach To Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction― Circulation, 2019, 139, 990-991.	1.6	2
417	Ventriculoseptal Rupture Caused by Takotsubo Syndrome. JACC: Case Reports, 2020, 2, 2072-2077.	0.3	2
418	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events. BioDrugs, 2012, 26, 217-233.	2.2	2
419	Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis. Minerva Cardioangiologica, 2020, 68, 47-50.	1.2	2
420	Time restricted feeding: old tools, new packaging?. Minerva Cardioangiologica, 2020, 68, 539-541.	1.2	2
421	Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience. Cardio-Oncology, 2021, 7, 40.	0.8	2
422	Clinical relevance of apoptosis in early and late post-infarction left ventricular remodeling. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2002, 3, 699-705.	0.1	2
423	Acute Effects of Liothyronine Administration on Cardiovascular System and Energy Metabolism in Healthy Volunteers. Frontiers in Endocrinology, 2022, 13, 843539.	1.5	2
424	Arrhythmic Recurrence and Outcomes in Patients Hospitalized With First Episode of Electrical Storm. American Journal of Cardiology, 2022, 172, 40-47.	0.7	2
425	Transient left ventricular dysfunction following chimeric antigen receptor Tâ€cellâ€mediated encephalopathy: A form of stress cardiomyopathy. EJHaem, 2022, 3, 231-234.	0.4	2
426	Cyclooxygenase-2 in myocardial ischemia. Journal of the American College of Cardiology, 2003, 42, 1714.	1.2	1
427	The Hurdles of Warfarin and the Hurdles of Clinical Practice. Stroke, 2006, 37, 2867-2867.	1.0	1
428	Late Open Artery Hypothesis in Clinical Practice—Is It a "Dead―Issue?. American Journal of Cardiology, 2008, 101, 1520-1521.	0.7	1
429	Revisiting the role of percutaneous revascularization versus medical therapy for later infarct-related artery occlusion (letter of comment on loannidis and Katritsis. Am Heart J.) Tj ETQq1 1 0.784314	rg₿ī[.⊉Ove	rloak 10 Tf 5(
430	Benefits of coronary revascularization in stable patients in the short and long term after acute myocardial infarction. Interventional Cardiology, 2010, 2, 67-76.	0.0	1
431	Effects of PI3KÎ ³ Inhibition Using AS-605240 in Acute Myocardial Infarction. Circulation Research, 2010, 107, e5; author reply e6-7.	2.0	1
432	Letter by Dixon et al Regarding Article, "Watching Television and Risk of Mortality From Pulmonary Embolism Among Japanese Men and Women: The JACC Study (Japan Collaborative Cohort)― Circulation, 2016, 134, e499-e500.	1.6	1

#	Article	IF	CITATIONS
433	Treatment of Hypertension toÂPrevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors. JACC: Heart Failure, 2018, 6, 85.	1.9	1
434	A case report of locally invasive Aspergillus fumigatus infection in a patient on canakinumab. European Heart Journal - Case Reports, 2018, 2, yty098.	0.3	1
435	Noninvasive Hemodynamic Monitoring of Cocaine-Induced Changes in Cardiac Output and Systemic Vascular Resistance in Subjects With Chronic Cocaine Use Disorder. Journal of Cardiovascular Pharmacology, 2019, 74, 528-534.	0.8	1
436	Cardiovascular Pharmacology of the NLRP3 Inflammasome. Journal of Cardiovascular Pharmacology, 2019, 74, 173-174.	0.8	1
437	SCUBE Diving. JACC Basic To Translational Science, 2020, 5, 1093-1094.	1.9	1
438	Deciphering post-infarct inflammation: Should it heal, would it hurt?. Journal of Nuclear Cardiology, 2020, 27, 2100-2102.	1.4	1
439	Inverse associations between parasympathetic activity and cognitive flexibility in African Americans: Preliminary findings. International Journal of Psychophysiology, 2020, 155, 204-209.	0.5	1
440	Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?. Journal of Cardiovascular Pharmacology, 2021, 78, 331-333.	0.8	1
441	Differences in heart rate among recent marijuana use groups. Minerva Cardiology and Angiology, 2021, 69, 469-473.	0.4	1
442	Italian cardiovascular expats: global leaders with Italian heartstrings. Minerva Cardioangiologica, 2020, 68, 167-171.	1.2	1
443	Abstract 2320: Long Acting Erectile Dysfunction Drug Tadalafil Limits Myocardial Ischemia/Reperfusion Injury and Preserves Left Ventricular Function through Protein Kinase G Dependent Pathway. Circulation, 2008, 118, .	1.6	1
444	Heart failure clinical trial enrollment at a rural satellite hospital. Contemporary Clinical Trials, 2022, 115, 106731.	0.8	1
445	Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure. American Journal of Cardiology, 2022, , .	0.7	1
446	Antioxidant Vitamins and Coronary Disease. New England Journal of Medicine, 2002, 346, 1092-1093.	13.9	0
447	Early revascularisation for myocardial infarction. Lancet, The, 2002, 360, 1603.	6.3	0
448	Soluble interleukin-2 receptor: is there a role in ischaemic cardiomyopathy?. European Journal of Clinical Investigation, 2003, 33, 1020-1020.	1.7	0
449	Re: Kodaet al. Myocytes positive forin situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure.J Pathol 2003; 199: 229-236. Journal of Pathology, 2003, 201, 337-339.	2.1	0
450	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 231-233.	0.0	0

#	Article	IF	CITATIONS
451	Drawbacks of Nonrandomized Trials in Acute Coronary Syndromes. American Journal of Cardiology, 2006, 97, 151.	0.7	Ο
452	From Chaotic to Coordinated Clinical Research: The Case of Acetylcysteine. Archives of Internal Medicine, 2006, 166, 1668.	4.3	0
453	Ximelagatran Versus Warfarin in the Prevention of Atrial Fibrillation–Related Stroke: Both Sides of the Story. Stroke, 2007, 38, e57.	1.0	0
454	Recurrent angina and the problem of inadequate/inappropriate revascularization: reply. European Heart Journal, 2007, 28, 2951-2952.	1.0	0
455	IL-1-4 Interleukin-1 blockade prevents unfavorable cardiac remodeling following acute myocardial infarction. Cytokine, 2010, 52, 9-10.	1.4	Ο
456	PS1-10 Induction of the NLRP3 inflammasome in cardiac myocytes. Cytokine, 2010, 52, 19.	1.4	0
457	PS3-30 Modulation of caspase-1 activity in experimental acute myocardial infarction using exogenous α1-Antitrypsin. Cytokine, 2010, 52, 88.	1.4	0
458	PS2-049. Enhanced plasma Interleukin-1 activity contributes to cardiac dysfunction in heart failure. Cytokine, 2011, 56, 76.	1.4	0
459	SILDENAFIL PREVENTS RADIATION-INDUCED CARDIOMYOPATHY IN THE MOUSE. Journal of the American College of Cardiology, 2011, 57, E190.	1.2	0
460	Percutaneous Coronary Intervention for Persistent Occlusion of the Infarct-Related Artery: An Expanded View of the Evidence. Archives of Internal Medicine, 2011, 171, 1962.	4.3	0
461	Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts. Current Respiratory Medicine Reviews, 2012, 8, 116-122.	0.1	0
462	Meta-analysis of coronary CT angiography in the emergency department: reply. European Heart Journal Cardiovascular Imaging, 2013, 14, 607-608.	0.5	0
463	Colchicine in Stable Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 538.	1.9	0
464	Commentary: Which Comes First, the Phoenix or the Flame? Reflections on the Role of Inflammation in Patients Undergoing Lower Limb Revascularization for Peripheral Artery Disease. Journal of Endovascular Therapy, 2015, 22, 240-242.	0.8	0
465	Letter by Seropian and Abbate Regarding Article, "Effect of Tumor Necrosis Factor Inhibitor Treatment on Proximal Right Coronary Chronic Total Occlusion in a Patient With Rheumatoid Arthritis― Circulation, 2015, 132, e162.	1.6	0
466	Relationship between Plasma Biomarkers and Response to IL-1 Blockade in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2016, 22, S29.	0.7	0
467	IPW-5371 Proves Effective as a Radiation Countermeasure by Mitigating Radiation-Induced Late Effects. Radiation Research, 2016, , .	0.7	0
468	Successful Weight Loss with Low Carbohydrate Ketogenic Diet (LCKD) Significantly Reduced Visceral Fat and Increased Fat Free Mass in Obese. Gastroenterology, 2017, 152, S831.	0.6	0

#	Article	IF	CITATIONS
469	Targeting Neurohormonal Activation in Pulmonary Arterial Hypertension. JACC Basic To Translational Science, 2017, 2, 36-38.	1.9	ο
470	EARLY DIASTOLIC MITRAL ANNULAR VELOCITY AT PEAK EXERCISE DETERMINES PEAK AEROBIC EXERCISE CAPACITY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology, 2017, 69, 889.	1.2	0
471	MANAGEMENT OF OBESITY IN PATIENTS WITH DIASTOLIC DYSFUNCTION. Journal of the American College of Cardiology, 2017, 69, 2106.	1.2	Ο
472	Cirrhotic Cardiomyopathy and Liver Transplantation. , 2017, , 449-462.		0
473	Interleukin-1a Blockade Reduce Acute Myocardial Ischemic Injury In The Mouse. Journal of Molecular and Cellular Cardiology, 2017, 112, 150.	0.9	0
474	Response to letter from Dr. Madias. Autonomic Neuroscience: Basic and Clinical, 2018, 210, 82.	1.4	0
475	Letter by Potere et al Regarding Article, "Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages― Circulation, 2019, 139, 1979-1980.	1.6	0
476	Comment on Hypoglycemia and hyperglycemia are risk factors for falls in the hospital population by Berra et al Acta Diabetologica, 2020, 57, 109-110.	1.2	0
477	Heart Rate Variability as a Link Between Brain-Elicited Substance Cues and Substance Use Severity. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 560-561.	1.1	0
478	Clinical features and outcomes between African American and Caucasian patients with Takotsubo Syndrome. Minerva Cardiology and Angiology, 2021, 69, 750-759.	0.4	0
479	Pericarditis and Sacroiliitis in a World Traveler. JACC: Case Reports, 2021, 3, 1322-1326.	0.3	0
480	Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. Journal of Cardiovascular Pharmacology, 2021, 78, 407-410.	0.8	0
481	High-Sensitivity C-Reactive Protein for Risk Assessment in Acute Coronary Syndromes. , 2006, , 261-275.		0
482	Mitigation of Heart Failure Progression with Sildenafil Involves Inhibition of RhoA/Rhoâ€Kinase Pathway. FASEB Journal, 2010, 24, 601.13.	0.2	0
483	The Pathobiology of Chronic Right Ventricular Failure. Respiratory Medicine, 2015, , 283-301.	0.1	Ο
484	Early changes in NT-proBNP levels predict new-onset heart failure in patients with STEMI. Minerva Cardiology and Angiology, 2020, , .	0.4	0
485	Chryseobacterium bacteraemia in a patient with heart failure: case report and literature review. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.3	0
486	In-hospital death among patients undergoing percutaneous coronary intervention: A root-cause analysis. Cardiovascular Revascularization Medicine, 2022, , .	0.3	0

#	Article	IF	CITATIONS
487	277 Heart Failure Clinical Trial Enrollment at a Rural Satellite Hospital. Journal of Clinical and Translational Science, 2022, 6, 47-47.	0.3	0
488	OUP accepted manuscript. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	0
489	Differences in Immune Cell Mitochondrial Function in Black and White Patients with Heart Failure with Preserved Ejection Fraction. FASEB Journal, 2022, 36, .	0.2	0